🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 36316D104
- Market Cap
- Large Cap · $2 Billion
- Previous Symbol
- GLYPP (changed 5/14/2015)
Business: Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.
Notes: Mechelen, Belgium; 14 May 2015 -- Galapagos NV announced today the pricing of its global offering totaling $275 million gross proceeds of 6,550,000 new ordinary shares, consisting of 4,996,522 American Depositary Shares (ADSs) at $42.05 per ADS, and 1,553,478 ordinary shares at a price of €37.00 per share, both before underwriting discounts. These shares were placed in a concurrent public offering in the US and private placement in Europe (together the global offering). The price per ADS was based on €37.00 per ordinary share at an exchange rate of $1.1365 per Euro. Each of the ADSs offered represents the right to receive one ordinary share.
Company Contact
- CEO
- Onno van de Stolpe
- CFO
- Bart Filius
- Investor Relations
- ir@glpg.com